7, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade name: Ka... ...
This patient-centered hospital building establishes a strong connection to its Harlem community by celebrating a historically significant mural at a civic scale. The high-performance curtain wall facade replicates three colorful panels from a Works Progress Administration (WPA) mural uncovered and restored...
The appropriateness of the antibiotic therapy was found to differ non significantly for the selection of prophylactic antibiotic (p = 0.552) and for the timing of first dose administration (p = 0.061) between A and B periods. The total compliance was decreased non significantly (P =...